Benzinga··Vandana SinghPfizer Extends Vyndamax Patent Protection to 2031, Bolstering Post-Decade Revenue Outlook
Pfizer beats Q1 2026 expectations with $0.75 EPS and $14.45B in sales. Patent settlement extends Vyndamax protection to June 2031, ensuring revenue stability.
PFErevenue guidanceQ1 earnings